Target intelligence / Profile preview

Grainyhead-like transcription factor 1 (GRHL1)

Target
GRHL1
Molecular classification
Transcription factor
01

Overview

Grainyhead-like transcription factor 1 (GRHL1) is a member of the grainyhead family of transcription factors with a highly conserved, immunoglobulin-like DNA binding domain structurally related to p53[2]. GRHL1 plays a critical role in regulating epidermal differentiation and the expression of cell adhesion molecules, such as desmoglein 1, which is essential for maintaining skin integrity and proper hair anchorage[3][5]. It functions predominantly as a homodimer or may form heterodimers with related family members and is important during embryonic development[2][5]. In cancer biology, GRHL1 has context-dependent roles, acting as a tumor suppressor or promoter depending on tissue type: it is associated with altered cancer cell proliferation, and its dysregulation affects cell cycle genes[1]. Loss of GRHL1 in animal models leads to skin barrier defects, abnormal desmosomes, and increased risk for malignant progression to squamous cell carcinoma[3]. Mutations in the GRHL1 gene are also linked to inherited deafness and corneal dystrophy[5]. As a potential drug target, its involvement in regulating cell cycle genes in cancer is under investigation, but no specific drugs are currently known to target it directly[1][4][5].

Other names
Grainyhead-like protein 1 homologLBP32MGRTFCP2L2LBP-32NH32Transcription factor CP2-like 2Mammalian grainyhead
02

Biological functions

Regulation of epidermal differentiationActivation of cell adhesion molecule expression (e.g., desmoglein 1)Cell cycle regulationDNA binding via immunoglobulin-like DNA binding domain
03

Disease associations

Cancer (varies by type—reported in lung, colon, esophageal, and squamous cell carcinoma)Skin disorders (e.g., epidermal barrier defects, hair follicle anchorage abnormalities)Deafness (Autosomal Dominant 28)Corneal dystrophy (Posterior polymorphous, type 2)
04

Safety considerations

Potential impact on epidermal homeostasis and skin integrity if targeted therapeuticallyPotential tumor suppressor functions suggest risks if inhibited inappropriately
05

Biomarkers

GRHL1 expression (for prognosis in certain cancers, e.g., non-small cell lung cancer, colon cancer, esophageal squamous cell carcinoma)

Beyond the preview

Go deeper on Grainyhead-like transcription factor 1 (GRHL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grainyhead-like transcription factor 1 (GRHL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call